Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HENLIUS Receives Approval for Clinical Trials of HLX22 and HLX87 Combination Therapy for Breast Cancer Treatment
Recommend 2 Positive 1 Negative 0 |
||||
|
||||
|
HENLIUS (02696.HK) announced that the applications for phase 2/3 clinical trials of HLX22, a license-in innovative anti-HER2 monoclonal antibody subsequently self-developed by the company, in combination with HLX87 for injection (antibody-drug conjugate targeting HER2) (1) for first-line treatment of HER2-positive breast cancer (BC); and (2) for neoadjuvant treatment for HER2-positive breast cancer (BC neo) have been approved by China's National Medical Products Administration, respectively. The company proposes to commence relevant clinical trials in Chinese Mainland when the conditions are met. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
